Table 2. Individual patient, treatment, and outcome characteristics.
| Pt No. | Sex | Age (years) | Prior chemotherapy regimen | Disease extension | Line of GEM/CAP therapy | No. of cycles | Best response | CAP maintenance | PFS (months) | OS (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 46 | PEM/DDP/BEV, TAX/BEV | Pleura; abdominal, cervical, thoracic, supraclavicular LNs | 3 | 2 | PD | No | 4.0 | 17.3 |
| 2 | M | 65 | DOC/NDP, GEM/NDP, TAX/NDP | Liver; lung; pleura; abdominal, thoracic, supraclavicular LNs | 4 | 6 | SD | Yes | 8.8 | 9.2+ |
| 3 | M | 62 | PEM/DDP, DOC/BEV, icotinib | Liver; lung; pleura; bone; thoracic, supraclavicular LNs | 4 | 12 | PR | No | 16.7 | 41.5 |
| 4 | F | 51 | VIN/DDP, TAX/DDP | Thoracic LNs | 3 | 4 | SD | No | 11.5 | 33.4+ |
| 5 | F | 52 | PEM/DDP, TAX/CBP | Pleura; lung; supraclavicular, thoracic LNs | 3 | 8 | PR | No | 9.3 | 17.9 |
| 6 | M | 39 | PEM/DDP, DOC/BEV | Thoracic LNs | 3 | 4 | SD | No | 4.6+ | 73.5+ |
| 7 | F | 51 | TAX/DDP, DOC/GEM, clinical trial | Pleura; lung; supraclavicular, thoracic LNs | 4 | 4 | SD | No | 6.9 | 27.7+ |
| 8 | F | 45 | TAX/DDP, TAX/DDP, PEM/CBP/BEV | Liver; lung; pleura; bone; abdominal, thoracic, supraclavicular LNs | 4 | 9 | PR | No | 8.8 | 26.6+ |
| 9 | F | 48 | TAX/NDP | Lung; abdominal, thoracic, supraclavicular LNs | 2 | 4 | PR | Yes | 18.3 | 52.9+ |
| 10 | M | 43 | TAX/DDP, PEM, DOC/GEM, TAX/CAP | Thoracic LNs | 5 | 5 | SD | No | 21.5 | 33.9+ |
| 11 | F | 38 | TAX/NDP | Liver; bone; abdominal, thoracic, supraclavicular LNs | 2 | 6 | PR | Yes | 6.4 | 19.6 |
| 12 | M | 43 | TAX/NDP, GEM/DDP, tegafur, etoposide | Liver; thoracic, supraclavicular LNs | 5 | 4 | PR | Yes | 6.6 | 16.0 |
| 13 | M | 56 | TAX/DDP | Abdominal, thoracic LNs | 2 | 6 | PR | Yes | 29.3+ | 29.3+ |
| 14 | M | 37 | PEM/DDP/BEV, TAX/CBP/BEV, DOC/BEV, PEM/CBP/BEV | Liver; lung; pleura; thoracic LNs | 5 | 3 | PD | No | 2.0 | 4.1 |
| 15 | F | 35 | PEM/NDP | Thoracic LNs | 2 | 6 | SD | Yes | 20.7+ | 20.7+ |
| 16 | F | 45 | TAX/CBP | Liver; spleen; bone; abdominal, thoracic, supraclavicular LNs | 2 | 6 | PR | Yes | 11.0 | 21.6+ |
+, alive at data cutoff. Pt, patient; No., number; GEM, gemcitabine; CAP, capecitabine; PFS, progression-free survival; OS, overall survival; M, male; PEM, pemetrexed; DDP, cisplatin; BEV, bevacizumab; TAX, paclitaxel; LNs, lymph nodes; PD, progressive disease; DOC, docetaxel; NDP, nedaplatin; SD, stable disease; PR, partial response; F, female; VIN, vinorelbine; CBP, carboplatin.